On March 28, 2022, Nanjing Chiheal Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Chiheal Pharmaceutical") and Zhejiang Weikang Pharmaceutical Co., Ltd. (hereinafter referred to as "Weikang Pharmaceutical") signed a strategic cooperation agreement. The two parties will establish a strategic partnership, strengthening collaboration in areas such as pharmaceutical project selection, joint development, and contracted R&D, aiming to achieve mutual success.

The signing ceremony was attended by Dr. Zhang Zhefeng, Chairman of Chiheal Pharmaceutical; Mr. Liu Zhongliang, Chairman of Weikang Pharmaceutical; Ms. Kong Xiaoxia, President of Weikang Pharmaceutical; Mr. Dai Dexiong, Vice President of Weikang Pharmaceutical; and Mr. Zhong Desong, General Manager of the Investment Banking Division at Minsheng Securities Co., Ltd.

Following the signing ceremony, the two parties further discussed specific cooperation intentions and reached a consensus. In the future, they will engage in comprehensive collaboration in areas such as generic drugs, innovative drugs (e.g., anti-COVID-19 and anti-influenza therapies), and advanced formulations (e.g., liposomes and long-acting sustained-release preparations). The partnership aims to leverage each other's strengths, achieve synergy, and bring more high-quality products and technologies to market.